Open report — full analysis, no account required.
Sign up to generate reports and read filings that aren't on the open list.
Get notified when MDT files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsMedtronic names Dr. Kweli Thompson to lead Neuroscience as Brett Wall departs
Filed May 18, 2026 · Period ending May 18, 2026 · ~1 min read
Key Changes
-
medium
Dr. Kweli Thompson, currently SVP and President of Cardiac Rhythm Management, promoted to EVP and President of Neuroscience Portfolio effective June 1, 2026, replacing departing Brett Wall.
Item 5.02 verify on EDGAR → -
medium
Brett Wall departing as EVP and President of Neuroscience Portfolio; will remain through September 1, 2026 to assist with transition and receive standard executive severance.
Item 5.02 verify on EDGAR →
Summary
Medtronic disclosed a planned leadership transition in its Neuroscience Portfolio, one of the company's key business segments. Brett Wall is stepping down as Executive Vice President and President of Neuroscience, with Dr. Kweli Thompson taking over the role effective June 1, 2026. Wall will remain with the company through early September to support the handover. The succession appears orderly and internally sourced.
Dr. Thompson currently leads Cardiac Rhythm Management as Senior Vice President and President, indicating familiarity with Medtronic's medical device operations and commercial strategy. The three-month transition period and standard severance arrangement suggest a planned departure rather than an abrupt exit. For retail holders, this is a routine executive change with no immediate operational concerns, though investors may want to monitor Neuroscience segment performance in coming quarters as the new leadership settles in.
Section-by-Section Diff
Event · Item 5.02 — Departure of Directors or Certain Officers; Election of Directors; Compensation
Item 5.02 — Departure of Directors or Certain Officers; Election of Directors; Compensation filed; see Key Changes for terms.
Added in current filing · verify on EDGAR →
Dr. Kweli Thompson, currently Senior Vice President and President, Cardiac Rhythm Management, will be assuming the role of Executive Vice President and President, Neuroscience Portfolio, effective June 1, 2026
Dr. Kweli Thompson, currently leading Cardiac Rhythm Management, will be promoted to Executive Vice President and President of the Neuroscience Portfolio effective June 1, 2026. This represents an internal succession for a key business segment leadership role.
Show 1 minor / wording change
Added in current filing · verify on EDGAR →
Mr. Wall is entitled to and will receive severance payments and benefits consistent with Medtronic’s severance practices for executive officers as described in Medtronic’s 2025 Proxy Statement filed with the Securities and Exchange Commission on August 25, 2025
Brett Wall will receive severance payments and benefits according to the company's standard executive severance practices previously disclosed in the 2025 proxy statement. The specific terms are not detailed in this filing.
Thanks — your feedback helps us improve report quality.
Figures/quotes linked to EDGAR · Narrative written by AI · Jun 22, 2026 · How we verify